Gen-Wealth Partners’s Beam Therapeutics BEAM Stock Holding History

Gen-Wealth Partners’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$429	Hold	18	–	–	﹤0.01%	698
2025 Q4	$499	Hold	18	–	–	﹤0.01%	661
2025 Q3	$437	Hold	18	–	–	﹤0.01%	659
2025 Q2	$306	Hold	18	–	–	﹤0.01%	625
2025 Q1	$352	Hold	18	–	–	﹤0.01%	591
2024 Q4	$446	Hold	18	–	–	﹤0.01%	623
2024 Q3	$405	Hold	18	–	–	﹤0.01%	638
2024 Q2	$422	Hold	18	–	–	﹤0.01%	623
2024 Q1	$595	Buy	+18	New	+$561	﹤0.01%	602

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Gen-Wealth Partners's BEAM Position: Q1 2026 in Review

Gen-Wealth Partners held its Beam Therapeutics (BEAM) position steady in Q1 2026 at 18 shares worth $429. The position accounts for ﹤0.01% of the portfolio, ranked #698.

Gen-Wealth Partners first reported a position in BEAM in Q1 2024 and has held it in 9 quarters since. The position peaked at $595 in Q1 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

Gen-Wealth Partners held 18 shares of Beam Therapeutics worth $429 as of Q1 2026.
Gen-Wealth Partners left its Beam Therapeutics share count unchanged in Q1 2026.
Beam Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #698 holding.
Gen-Wealth Partners first reported a position in Beam Therapeutics in Q1 2024 and has held it in 9 quarters since.
Gen-Wealth Partners's Beam Therapeutics position peaked at $595 in Q1 2024.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.